Plain-English translation of NCT06783569 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Solid Tumors research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called for people with advanced solid tumors—cancers that have spread or progressed despite standard treatment. The trial has two parts: first, researchers will carefully increase the dose in small groups of patients to find the safest dose, then expand to test that dose in more patients. The goal is to understand how safe the medication is and whether it helps shrink tumors.
Many patients with advanced cancers run out of standard treatment options, and their cancer continues to grow. This medication represents a new approach that researchers hope could help people whose cancers no longer respond to existing therapies.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion on days 1, 8, and 15 of each 28-day treatment cycle. You'll have imaging scans (CT or MRI) every 8 weeks for the first year, then every 12 weeks after that, along with regular blood draws to check how the medication is working and how your body is handling it. The trial will last as long as the treatment is helping and you're tolerating it well.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China